Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., … Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet Oncology, 23(2), 259–269. https://doi.org/10.1016/s1470-2045(21)00718-x